GEN Exclusives

More »

GEN News Highlights

Back to Item »

DBV Raises $25.5M in Series C for Clinical-Stage Food Allergy Desensitization Technology

DBV’s Viaskin platform is already undergoing human testing in patients with peanut and milk allergies.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?